Export citation

Show simple item record

dc.contributor.authorChao Ma*
dc.contributor.authorAntoni Ribas*
dc.contributor.authorRong Fan*
dc.date.accessioned2021-02-11T09:28:09Z
dc.date.available2021-02-11T09:28:09Z
dc.date.issued2014*
dc.date.submitted2015-12-03 13:02:24*
dc.identifier17750*
dc.identifier.issn16648714*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/42640
dc.description.abstractIn the past decade, significant progresses have taken place in the field of cancer immunotherapy. Tumor-targeting immunotherapies are being developed for most human cancers, including melanoma, prostate cancer, glioblastoma, sarcoma, lung carcinoma and hepatocellular carcinoma. The FDA has approved multiple molecular immunotherapeutics, such as Ipilimumab; cellular immunotherapies (e.g. adoptive cell transfer) are being tested in phase II/III clinical trials. Immunotherapetics has evolved into a sophisticated field: Multimodal therapeutic regimens are administrated to induce focused responses, curtail side- effects and improve therapeutic efficacy. The lack of effective clinical assessment tools remains a major challenge. Because of the intricacy of antitumor response, it is essential to scrutinize individual tumor-targeting immune cells and their functions at the finest details - molecules. In this regard, flow cytometry analysis modernized hematology and allows characterization of surface molecular signature on individual cells. More recently, microchip technologies and new variations of cytometry have enormously expanded the spectrum, throughout and multiplexity of single cell analysis. Nowadays, tens of millions of readouts can be generated through the course of a cancer immunotherapy to monitor the abundance, phenotype and a myriad of effector functions of single immune cells. At the same time, big data analytics and data mining methodologies have been adapted to achieve sensible diagnostic interpretations. Such a marriage of technology and analytics opens the door for informative point-of-care assessment of therapeutic efficacy and ensures timely therapeutic decisions. The new generation of personalized clinical diagnostics will revolutionize healthcare in the years to come.*
dc.languageEnglish*
dc.relation.ispartofseriesFrontiers Research Topics*
dc.subjectR5-920*
dc.subjectRC254-282*
dc.subject.otherimmune assessment*
dc.subject.othersingle cell analysis*
dc.subject.othercancer immunotherapy*
dc.subject.othertumor immunity*
dc.subject.otherimmune suppression*
dc.titleCancer Immunotherapy & Immuno-monitoring: Mechanism, Treatment, Diagnosis, and Emerging Tools*
dc.typebook
oapen.identifier.doi10.3389/978-2-88919-380-6*
oapen.relation.isPublishedBybf5ce210-e72e-4860-ba9b-c305640ff3ae*
virtual.oapen_relation_isPublishedBy.publisher_nameFrontiers Media SA
virtual.oapen_relation_isPublishedBy.publisher_websitewww.frontiersin.org
oapen.relation.isbn9782889193806*
oapen.pages97*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/